Highest-materiality recent filing
Omnicell Q1 revenue $310M (+15% YoY); raises FY2026 non-GAAP EBITDA/EPS guidance
GAAP net income $11M ($0.25/diluted) vs loss of $7M ($0.15 loss) in Q1 2025.
Omnicell Q4 rev $314M (+2% YoY), GAAP net loss $0.05/sh; FY26 revenue guide $1.215-1.255B
Q4 total revenues $314M (+2% YoY); full-year 2025 rev $1.185B (+7% YoY).
Omnicell launches Titan XT automated dispensing system powered by OmniSphere cloud platform
Launch of Omnicell Titan XT, a next-gen automated dispensing system for autonomous medication management, available now in US.
Omnicell Q3 rev $311M (+10% YoY), beats guidance; raises FY2025 outlook
Q3 revenue $311M (+10% YoY); GAAP EPS $0.12, non-GAAP EPS $0.51; non-GAAP EBITDA $41M.
Omnicell Q2 2025 revenue $291M (+5% YoY), beats guidance; raises FY2025 outlook
Total revenues $291M (+5% YoY); GAAP EPS $0.12, non-GAAP EPS $0.45.
CFO Nchacha Etta to depart; employment extended through Nov 15, 2025, or until successor appointed.
Omnicell raises Q2 and FY2025 profit outlook on tariff relief; authorizes $75M share buyback
Q2 Non-GAAP EBITDA guidance raised to $25-31M (from $22-30M); Non-GAAP EPS raised to $0.24-0.34 (from $0.19-0.32).
On March 12, 2025, Omnicell, Inc. (“Omnicell” or the “Company”) filed a Current Report on Form 8-K disclosing that Nchacha Etta would step down from his role as Executive Vice President, Chief Financial Officer of the Company, effective September 15, 2025 or until a successor is named.
Max materiality 0.80 · Median 0.70 · Most common event earnings